Neuropathology of depression in Alzheimer's disease: Current knowledge and the potential for new treatments

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 27-41

  Khundakar, Ahmad A ^a   Thomas, Alan J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Antidepressants; Cognitive impairment; Dementia; Depression; Late life

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ANTERIOR CINGULATE; CAUDATE NUCLEUS; DEMENTIA; DENTATE GYRUS; DEPRESSION; DISEASE ASSOCIATION; GLIA CELL; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LATE LIFE DEPRESSION; MILD COGNITIVE IMPAIRMENT; MONOAMINERGIC SYSTEM; NERVE CELL; NEUROANATOMY; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; PYRAMIDAL NERVE CELL; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; THALAMUS; VASCULAR AMYLOIDOSIS; WHITE MATTER; ANIMAL; BRAIN; COMPLICATION; DIAGNOSTIC USE; DRUG EFFECTS; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; HUMANS;

EID: 84920830713     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-148003     Document Type: Review

References (178)

1. Wortmann M (2012) Dementia: A global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4, 40.
2. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 3, 73.
3. Ballard C, Neill D, O'Brien J, McKeith IG, Ince P, Perry R (2000) Anxiety, depression and psychosis in vascular dementia: Prevalence and associations. J Affect Disord 59, 97-106.
4. Ritchie K, Touchon J, Ledesert B (1998) Progressive disability in senile dementia is accelerated in the presence of depression. Int J Geriatr Psychiatry 13, 459-461.
5. Burns A, Lewis G, Jacoby R, Levy R (1991) Factors affecting survival in Alzheimer's disease. Psychol Med 21, 363-370.
6. Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, Zmuda MD, Bhalla R, Meltzer CC, Pollock BG, Reynolds CF 3rd, Becker JT (2004) The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry 61, 587-595.
7. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K (2006) Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the Cardiovascular Health Study. Arch Gen Psychiatry 63, 273-279.
8. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA (2012) Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 69, 493-498.
9. Heun R, Kockler M, Ptok U (2002) Depression in Alzheimer's disease: Is there a temporal relationship between the onset of depression and the onset of dementia? Eur Psychiatry 17, 254-258.
10. Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, van der Mast RC (2004) Temporal relation between depression and cognitive impairment in old age: Prospective population based study. BMJ 329, 881.
11. Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ (2008) Amyloid-associated depression: A prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65, 542-550.
12. Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, PedersenNL(2009) Depression as a risk factor or prodromal feature for dementia? Findings in a populationbased sample of Swedish twins. Psychol Aging 24, 373-384.
13. Berger AK, Fratiglioni L, Forsell Y,Winblad B, Backman L (1999) The occurrence of depressive symptoms in the preclinical phase of AD: A population-based study. Neurology 53, 1998-2002.
14. Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS (1999) Depressive symptoms and cognitive decline in nondemented elderlywomen:Aprospective study. Arch Gen Psychiatry 56, 425-430.
15. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-538.
16. Barnes DE,YaffeK(2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10, 819-828.
17. Banerjee S, Hellier J, DeweyM, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz- Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A,Walwyn R,Wilson K, Burns A (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378, 403-411.
18. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV,Munro CA, Meinert CL, Lyketsos CG (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18, 136-145.
19. Weintraub D, Rosenberg PB, DryeLT,Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG (2010) Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry 18, 332-340.
20. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9, 357-381.
21. Bonelli RM, Cummings JL (2007) Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci 9, 141-151.
22. Vogt BA, Finch DM, Olson CR (1992) Functional heterogeneity in cingulate cortex: The anterior executive and posterior evaluative regions. Cereb Cortex 2, 435-443.
23. Drevets WC, Bogers W, Raichle ME (2002) Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 12, 527-544.
24. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders: Implications for neurocircuitry models of depression. Brain Struct Funct 213, 93-118.
25. Hercher C, Turecki G, Mechawar N (2009) Through the looking glass: Examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res 43, 947-961.
26. Bunge SA, Klingberg T, Jacobsen RB, Gabrieli JD (2000) A resource model of the neural basis of executive working memory. Proc Natl Acad Sci U S A 97, 3573-3578.
27. Kringelbach ML (2005) The human orbitofrontal cortex: Linking reward to hedonic experience. Nat Rev Neurosci 6, 691-702.
28. Mega MS, Cohenour RC (1997) Akinetic mutism: Disconnection of frontal-subcortical circuits. Neuropsychiatry Neuropsychol Behav Neurol 10, 254-259.
29. Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd, DeKosky ST, Becker JT (2008) Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 10, 345-357.
30. O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N (2004) A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 161, 2081-2090.
31. Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF, MacFall JR, Krishnan KR (2000) Hippocampal volume in geriatric depression. Biol Psychiatry 48, 301-309.
32. Ballmaier M, Toga AW, Blanton RE, Sowell ER, Lavretsky H, Peterson J, Pham D, Kumar A (2004) Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: An MRI-based parcellation of the prefrontal cortex. Am J Psychiatry 161, 99-108.
33. Dotson VM, Davatzikos C, Kraut MA, Resnick SM (2009) Depressive symptoms and brain volumes in older adults: A longitudinal magnetic resonance imaging study. J Psychiatry Neurosci 34, 367-375.
34. Lee SH, Payne ME, Steffens DC, McQuoid DR, Lai TJ, Provenzale JM, Krishnan KR (2003) Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression. Biol Psychiatry 54, 529-533.
35. Andreescu C, Butters MA, Begley A, Rajji T, Wu M, Meltzer CC, Reynolds CF 3rd, Aizenstein H (2008) Gray matter changes in late life depression-a structural MRI analysis. Neuropsychopharmacology 33, 2566-2572.
36. Butters MA, Aizenstein HJ, Hayashi KM, Meltzer CC, Seaman J, Reynolds CF 3rd, Toga AW, Thompson PM, Becker JT (2009) Three-dimensional surface mapping of the caudate nucleus in late-life depression. Am J Geriatr Psychiatry 17, 4-12.
37. Burke J, McQuoid DR, Payne ME, Steffens DC, Krishnan RR, Taylor WD (2011) Amygdala volume in late-life depression: Relationship with age of onset. Am J Geriatr Psychiatry 19, 771-776.
38. Sexton CE, Mackay CE, Ebmeier KP (2013) A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry 21, 184-195.
39. Herrmann LL, Le Masurier M, Ebmeier KP (2008) White matter hyperintensities in late life depression: A systematic review. J Neurol Neurosurg Psychiatry 79, 619-624.
40. Teodorczuk A, O'Brien JT, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund LO, Gouw A, Waldemar G, Schmidt R, Ferro JM, Chabriat H, Bazner H, Inzitari D (2007) White matter changes and late-life depressive symptoms: Longitudinal study. Br J Psychiatry 191, 212-217.
41. Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM, Epstein AA, Wilkins CH, Snyder AZ, Couture L, Schechtman K, McKinstry RC (2008) Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry 165, 524-532.
42. Steffens DC, Helms MJ, Krishnan KR, Burke GL (1999) Cerebrovascular disease and depression symptoms in the cardiovascular health study. Stroke 30, 2159-2166.
43. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM (2000) Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 57, 1071-1076.
44. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45, 1085-1098.
45. Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex inmood disorders. Proc Natl Acad Sci U S A 95, 13290-13295.
46. Cotter D, Mackay D, Landau S, Kerwin R, Everall I (2001) Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 58, 545-553.
47. Khundakar AA, Morris CM, Oakley AE, McMeekin W, Thomas AJ (2009) Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression. Br J Psychiatry 195, 163-169.
48. Khundakar A, Morris C, Oakley A, Thomas AJ (2011) A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression. Int Psychogeriatrics 23, 132-140.
49. Khundakar AA, Morris CM, Oakley AE, Thomas AJ (2011) Cellular pathology within the anterior cingulate cortex of patients with late-life depression: A morphometric study. Psychiatry Res 194, 184-189.
50. Van Otterloo E, O'Dwyer G, Stockmeier CA, Steffens DC, Krishnan RR, Rajkowska G (2009) Reductions in neuronal density in elderly depressed are region specific. Int J Geriatr Psychiatry 24, 856-864.
51. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, MeltzerHY, Uylings HB, Friedman L, Rajkowska G (2004) Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 56, 640-650.
52. Cobb JA, Simpson J, Mahajan GJ, Overholser JC, Jurjus GJ, Dieter L, Herbst N, May W, Rajkowska G, Stockmeier CA (2013) Hippocampal volume and total cell numbers in major depressive disorder. J Psychiatr Res 47, 299-306.
53. Boldrini M, Santiago AN, Hen R, Dwork AJ, Rosoklija GB, Tamir H, Arango V, John Mann J (2013) Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 38, 1068-1077.
54. Bowley MP, Drevets WC, Ongur D, Price JL (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52, 404-412.
55. Khundakar AA, Thomas AJ (2014) Cellular morphometry in late-life depression: A review of postmortem studies. Am J Geriatr Psychiatry 22, 122-132.
56. Alexopoulos GS, Kiosses DN, Choi SJ, MurphyCF, LimKO (2002) Frontal white matter microstructure and treatment response of late-life depression: A preliminary study. Am J Psychiatry 159, 1929-1932.
57. Bae JN, MacFall JR, Krishnan KR, Payne ME, Steffens DC, Taylor WD (2006) Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression. Biol Psychiatry 60, 1356-1363.
58. Shimony JS, Sheline YI, D'Angelo G, Epstein AA, Benzinger TL, Mintun MA, McKinstry RC, Snyder AZ (2009) Diffuse microstructural abnormalities of normal-appearing white matter in late life depression:Adiffusion tensor imaging study. Biol Psychiatry 66, 245-252.
59. Taylor WD, Macfall JR, Payne ME, McQuoid DR, Steffens DC, Provenzale JM, Krishnan KR (2007) Orbitofrontal cortex volume in late life depression: Influence of hyperintense lesions and genetic polymorphisms. Psychol Med 37, 1763-1773.
60. Hannestad J, Taylor WD, McQuoid DR, Payne ME, Krishnan KR, Steffens DC, Macfall JR (2006) White matter lesion volumes and caudate volumes in late-life depression. Int J Geriatr Psychiatry 21, 1193-1198.
61. Thomas AJ, O'Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH (2002) Ischemic basis for deep white matter hyperintensities in major depression: A neuropathological study. Arch Gen Psychiatry 59, 785-792.
62. Thomas AJ, Perry R, Kalaria RN, Oakley A, McMeekinW, O'Brien JT (2003) Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry 18, 7-13.
63. Swaab DF, Bao AM, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4, 141-194.
64. Alexopoulos GS, Young RC, Kocsis JH, Brockner N, Butler TA, Stokes PE (1984) Dexamethasone suppression test in geriatric depression. Biol Psychiatry 19, 1567-1571.
65. O'Brien JT, Ames D, Schweitzer I, Colman P, Desmond P, Tress B (1996) Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer's disease. Br J Psychiatry 168, 679-687.
66. Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57, 925-935.
67. Liston C, Gan WB (2011) Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo. Proc Natl Acad Sci U S A 108, 16074-16079.
68. Suri D, Vaidya VA (2013) Glucocorticoid regulation of brain-derived neurotrophic factor: Relevance to hippocampal structural and functional plasticity. Neuroscience 239, 196-213.
69. Haynes LE, Barber D, Mitchell IJ (2004) Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res 1026, 157-167.
70. Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE (2007) The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. Brain Cogn 65, 209-237.
71. Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME (1994) Glucocorticoid-induced impairment in declarative memory performance in adult humans. J Neurosci 14, 2047-2053.
72. Wingenfeld K, Wolf OT (2014) Stress, memory, and the hippocampus. Front Neurol Neurosci 34, 109-120.
73. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000) Hippocampal volume reduction in major depression. Am J Psychiatry 157, 115-118.
74. Lloyd AJ, Ferrier IN, Barber R, Gholkar A, Young AH, O'Brien JT (2004) Hippocampal volume change in depression: Late- and early-onset illness compared. Br J Psychiatry 184, 488-495.
75. Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, Lesage J, Lafontaine L, Lacroix A (2002) Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87, 1949-1954.
76. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 46, 1595-1602.
77. Gorevic PD, Goni F, Pons-Estel B, Alvarez F, Peress NS, Frangione B (1986) Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: Immunohistological studies. J Neuropathol Exp Neurol 45, 647-664.
78. Wong CW, Quaranta V, Glenner GG (1985) Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A 82, 8729-8732.
79. Podlisny MB, Lee G, Selkoe DJ (1987) Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science 238, 669-671.
80. Cruts M, Hendriks L, Van Broeckhoven C (1996) The presenilin genes: A new gene family involved in Alzheimer disease pathology. Hum Mol Genet 5 Spec No,1449-1455.
81. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
82. Citron M,WestawayD, XiaW, Carlson G, DiehlT, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67-72.
83. Meda L, Baron P, Scarlato G (2001) Glial activation in Alzheimer's disease: The role of Abeta and its associated proteins. Neurobiol Aging 22, 885-893.
84. Selkoe DJ (1994) Normal and abnormal biology of the betaamyloid precursor protein. Annu Rev Neurosci 17, 489-517.
85. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on A, Alzheimer's A (2012) National Institute on Aging- Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
86. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
87. Gotz J, Chen F, van Dorpe J, NitschRM(2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
88. Mi K, Johnson GV (2006) The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 3, 449-463.
89. Stoothoff WH, Johnson GV (2005) Tau phosphorylation: Physiological and pathological consequences. Biochim Biophys Acta 1739, 280-297.
90. Braak H, Braak E (1995) Staging of Alzheimer's diseaserelated neurofibrillary changes. Neurobiol Aging 16, 271- 278; discussion 278-284.
91. NelsonPT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, KukullWA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T,Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 71, 362-381.
92. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
93. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) Reexamining Alzheimer's disease: Evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18, 447-452.
94. Trojanowski JQ, Lee VM (2005) Pathological tau: A loss of normal function or a gain in toxicity? Nat Neurosci 8, 1136-1137.
95. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, FaganAM, IwatsuboT, JackCRJr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
96. Jellinger KA, Attems J (2003) Incidence of cerebrovascular lesions in Alzheimer's disease: A postmortem study. Acta Neuropathol 105, 14-17.
97. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28, 202-208.
98. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M (1997) Clinically defined vascular depression. Am J Psychiatry 154, 562-565.
99. Krishnan KR, Hays JC, Blazer DG (1997) MRI-defined vascular depression. Am J Psychiatry 154, 497-501.
100. Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13(Suppl 3), S115-S123.
101. Attems J, Jellinger K, Thal DR, Van Nostrand W (2011) Review: Sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 37, 75-93.
102. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. Neurology 58, 1629-1634.
103. Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: Incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14, 924-928.
104. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M (1987) Cerebral amyloid angiopathy in the aged. J Neurol 234, 371-376.
105. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J, Greenberg SM (2004) White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 63, 1606-1612.
106. Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV (2006) Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 60, 677-687.
107. Roman GC (1987) Senile dementia of the Binswanger type. Avascular form of dementia in the elderly. JAMA258, 1782-1788.
108. Gahr M, Nowak DA, Connemann BJ, Schonfeldt-Lecuona C (2013) Cerebral Amyloidal Angiopathy-a disease with implications for neurology and psychiatry. Brain Res 1519, 19-30.
109. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V (2006) Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63, 161-167.
110. Sweet RA, Hamilton RL, Butters MA, Mulsant BH, Pollock BG, Lewis DA, Lopez OL, DeKosky ST, Reynolds CF 3rd (2004) Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology 29, 2242-2250.
111. Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, Tsopelas ND, Lopresti BJ, Reynolds CF 3rd, DeKosky ST, Meltzer CC (2008) Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 22, 261-268.
112. Kumar A, Kepe V, Barrio JR, Siddarth P, Manoukian V, Elderkin-Thompson V, Small GW (2011) Protein binding in patients with late-life depression. Arch Gen Psychiatry 68, 1143-1150.
113. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE,Younkin LH, Petersen RC,Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
114. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol 5, 655-660.
115. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT (2004) Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 161, 1096-1102.
116. O'Brien J, Thomas A, Ballard C, Brown A, Ferrier N, Jaros E, Perry R (2001) Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biol Psychiatry 49, 130-136.
117. Tsopelas C, Stewart R, SavvaGM,Brayne C, Ince P, Thomas A, Matthews FE (2011) Neuropathological correlates of late-life depression in older people. Br J Psychiatry 198, 109-114.
118. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A (2013) Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci Biobehav Rev 37, 1363-1379.
119. Mann DM, Yates PO, Hawkes J (1982) The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 45, 113-119.
120. Mann DM, Yates PO, Marcyniuk B (1984) Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol 3, 199-205.
121. Lai MK, Tsang SW, Esiri MM, Francis PT, Wong PT, Chen CP (2011) Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. Psychopharmacology (Berl) 213, 431-439.
122. Parvizi J, Van Hoesen GW, Damasio A (2001) The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49, 53-66.
123. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60, 337-341.
124. Thomas AJ, Hendriksen M, Piggott M, Ferrier IN, Perry E, Ince P, O'Brien JT (2006) A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathol Appl Neurobiol 32, 296-303.
125. Hoogendijk WJ, Sommer IE, Pool CW, Kamphorst W, Hofman MA, Eikelenboom P, Swaab DF (1999) Lack of association between depression and loss of neurons in the locus coeruleus in Alzheimer disease. Arch Gen Psychiatry 56, 45-51.
126. Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59, 1151-1159.
127. McDonald WM, Richard IH, DeLong MR (2003) Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54, 363-375.
128. Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D (2011) Depressive symptoms in Alzheimer's disease and lewy body dementia: A one-year follow-up study. Dement Geriatr Cogn Disord 32, 143-149.
129. Schildkraut JJ, Gordon EK, Durell J (1965) Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J Psychiatr Res 3, 213-228.
130. Monyer H, Seeburg PH (1993) Constituents involved in glutamate receptor signaling. Hippocampus 3 Spec No,125- 129.
131. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95.
132. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62, 1310-1316.
133. Murrough JW (2012) Ketamine as a novel antidepressant: From synapse to behavior. Clin Pharmacol Ther 91, 303-309.
134. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57, 430-432.
135. Bhagwagar Z,Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, Matthews PM, Cowen PJ (2007) Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61, 806-812.
136. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61, 705-713.
137. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102, 15653-15658.
138. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32, 1888-1902.
139. Tsang SW, Vinters HV, Cummings JL, Wong PT, Chen CP, Lai MK (2008) Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol Aging 29, 1524-1532.
140. Pittenger C, Sanacora G, Krystal JH (2007) The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 6, 101-115.
141. Duman RS, Li N (2012) A neurotrophic hypothesis of depression: Role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci 367, 2475-2484.
142. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
143. Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 11, 29-37.
144. Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ (2000) Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 175, 81-90.
145. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56, 933-944.
146. Julien C, Tremblay C, Bendjelloul F, Phivilay A, Coulombe MA, Emond V, Calon F (2008) Decreased drebrin mRNA expression in Alzheimer disease: Correlation with tau pathology. J Neurosci Res 86, 2292-2302.
147. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, Kaye J, Manczak M (2005) Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction. J Alzheimers Dis 7, 103-117; discussion 173-180.
148. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives. J Neurochem 60, 1589-1604.
149. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170.
150. Korey SR, Scheinberg L, Terry R, Stein A (1961) Studies in presenile dementia. Trans Am Neurol Assoc 86, 99-102.
151. Lowe SL, Bowen DM, Francis PT, Neary D (1990) Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38, 571-577.
152. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11, 97-116.
153. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144, 97-112.
154. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang- Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Pina-Crespo JC, Lipton SA (2013) Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A 110, E2518-2527.
155. Francis PT (2009) Altered glutamate neurotransmission and behaviour in dementia: Evidence from studies of memantine. Curr Mol Pharmacol 2, 77-82.
156. Francis PT, Parsons CG, Jones RW (2012) Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother 12, 1351-1365.
157. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, RydelRE(1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12, 376-389.
158. Koh JY,Yang LL, CotmanCW(1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533, 315-320.
159. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, NairnAC, SalterMW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
160. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, Konya C, Sebens JB, Korf J, Nyakas C, Zarandi M, Soos K, Penke B, Luiten PG (2000) betaamyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 12, 2735-2745.
161. Topper R, Gehrmann J, Banati R, Schwarz M, Block F, Noth J, KreutzbergGW(1995) Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol 89, 23-28.
162. Couratier P, Lesort M, Sindou P, Esclaire F,Yardin C, Hugon J (1996) Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 27, 259-273.
163. Citri A, Malenka RC (2008) Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology 33, 18-41.
164. Ryan B, Musazzi L, Mallei A, Tardito D, Gruber SH, El Khoury A, Anwyl R, Racagni G, Mathe AA, Rowan MJ, Popoli M (2009) Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol 12, 553-559.
165. Wolkowitz OM, Reus VI, Mellon SH (2011) Of sound mind and body: Depression, disease, and accelerated aging. Dialogues Clin Neurosci 13, 25-39.
166. Khundakar AA, Zetterstrom TS (2011) Effects of GABAB ligands alone and in combination with paroxetine on hippocampal BDNF gene expression. Eur J Pharmacol 671, 33-38.
167. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D (1990) Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 9, 3545-3550.
168. Binder DK, Scharfman HE (2004) Brain-derived neurotrophic factor. Growth Factors 22, 123-131.
169. Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5, 311-322.
170. Khundakar AA, Zetterstrom TS (2006) Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res 1106, 12-20.
171. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5, 405-414.
172. Rajkowska G, Miguel-Hidalgo JJ, Dubey P, Stockmeier CA, Krishnan KR (2005) Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry 58, 297-306.
173. Gong R, Park CS, Abbassi NR, Tang SJ (2006) Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem 281, 18802-18815.
174. Duman RS, Li N, Liu RJ, DuricV, AghajanianG(2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-41.
175. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005) Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136, 29-37.
176. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
177. Yoon SC, Seo MS, Kim SH, Jeon WJ, Ahn YM, Kang UG, Kim YS (2008) The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci Lett 434, 23-28.
178. Hoeffer CA, Klann E (2010) mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33, 67-75.